SHEDDING POUNDS, DELIVERING GAINS.

BANK of America Corp. 055169452 ; NOVO Nordisk A/S NVO

A new class of weight-loss drugs that help people lose weight without dieting or exercising is showing promise for investors. These pharmaceuticals, known as GLP-1s, enable obese and overweight individuals to lose 15% to 20% of their body weight. The success of these drugs could have implications beyond weight loss, potentially impacting snack makers, packaged-food firms, and medical device makers. The market for obesity drugs is projected to grow significantly, reaching $100 billion by 2030. The article highlights two leading companies in this space, Eli Lilly and Novo Nordisk, as well as other potential competitors like Amgen, Viking Therapeutics, and Structure Therapeutics. [Extracted from the article]

Copyright of Kiplinger Personal Finance is the property of Future Publishing Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)